Neurology
RSSArticles
-
Preventing 90% of Stroke with 10 Modifiable Risk Factors
Controlling 10 modifiable risk factors would prevent 90.7% of strokes, according to results from a 32-country study.
-
Reducing Cardiovascular Events in Older Adults Through Blood Pressure Control
Among ambulatory adults ≥ 75 years of age, treating to a systolic blood pressure (SBP) target of < 120 mmHg compared with an SBP target of < 140 mmHg resulted in a significantly lower rate of fatal and nonfatal major cardiovascular events and death from any cause.
-
Clinical Briefs
In this section:
-
Sofosbuvir and Velpatasvir Tablets (Epclusa)
Sofosbuvir and velpatasvir tablets are indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infections.
-
Reduced Cardiac Index Is Not Correlated with Renal Function in Heart Failure Patients
In a retrospective analysis of patients with acute decompensated heart failure who received a pulmonary artery catheter, there was no significant correlation between cardiac index and markers of renal function, contradicting the importance of cardiac output in renal dysfunction among patients with heart failure.
-
Should Lipid Measurements Be Obtained in the Fasting or Nonfasting State?
When attempting to determine whether fasting or nonfasting lipid measurements are most appropriate in an individual patient, it is important to first think carefully about the clinical scenario and consider what question the results answer.
-
Can a Brain Condition Affect the Heart?
A large, prospective cohort study in women with more than two decades of follow-up indicated a consistent link between migraine and cardiovascular disease events, including cardiovascular mortality.
-
Cerebral Microbleeds: Risk Factor for Symptomatic Intracerebral Hemorrhage
Cerebral microbleeds (CMBs), as visualized on gradient-echo or susceptibility-weighted MRI, are considered markers of bleeding-prone cerebral microvessels and constitute a significant and independent predictor of future intracerebral hemorrhage. -
Buprenorphine Implant for Subdermal Administration (Probuphine)
The FDA has approved the first buprenorphine implant for the treatment of opioid dependence. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Buprenorphine was previously approved as oral and sublingual tablets. The implant is marketed as Probuphine.
-
Human Adenovirus B7: Severe Infection
ABSTRACT & COMMENTARY: Patients with HAdV-B7 were more likely to be adults and to have longer hospital stays.